非酒精性脂肪性肝病流行现状及危险因素研究进展

doi:10.12114/j.issn.1007-9572.2023.0893

摘要/Abstract

摘要： 非酒精性脂肪性肝病是一种进行性疾病，与乙型病毒性肝炎、丙型病毒性肝炎、酒精性肝病共同构成全球慢性肝病的主要病因。非酒精性脂肪性肝病若不进行有效干预，可逐渐恶化为非酒精性脂肪性肝炎、脂肪性肝纤维化、肝硬化甚至肝癌等，并可能在将来成为终末期肝病的主要原因。世界范围内，非酒精性脂肪性肝病的患病率、发病率正在不断增加，危害日趋显著。本文在进行大量资料搜集与文献阅读后，对非酒精性脂肪性肝病在性别、地区等方面的流行病学特征进行分析，同时针对激素、环境等危险因素对非酒精性脂肪性肝病可能造成的影响进行讨论，为非酒精性脂肪性肝病预防控制提供新的思路。

关键词: 非酒精性脂肪性肝病, 流行病学, 危险因素, 综述

Abstract:

Non-alcoholic fatty liver disease (NAFLD) is a progressive disease. NAFLD, viral hepatitis B, viral hepatitis C, and alcoholic liver disease are the major cause of chronic liver disease in the world. Without effective intervention measures, NAFLD can gradually deteriorate to non-alcoholic steatohepatitis, fatty liver fibrosis, liver cirrhosis and even hepatocellular carcinoma, and may become the main cause of end-stage liver disease in the future. The prevalence and incidence of NAFLD are increasing in the world, and the problem is becoming more and more serious. On the basis of relevant data collection and literature research, this article analyzes the epidemiological characteristics in gender and region of NAFLD, and discusses the possible effects of hormones and environment, and other risk factors on NAFLD, so as to provide new ideas for the prevention and control of NAFLD.

Key words: Non-alcoholic fatty liver disease, Epidemiology, Risk factors, Review

许耀珑,赵佳欣,杨立刚. 非酒精性脂肪性肝病流行现状及危险因素研究进展[J]. 中国全科医学, 2024, 27(30): 3825-3834. DOI: 10.12114/j.issn.1007-9572.2023.0893.
XU Yaolong,ZHAO Jiaxin,YANG Ligang. Epidemic Status and Risk Factors of Non-alcoholic Fatty Liver Disease[J]. Chinese General Practice, 2024, 27(30): 3825-3834. DOI: 10.12114/j.issn.1007-9572.2023.0893.

图/表 2

参考文献 112

[1]	FRIEDMAN S L, NEUSCHWANDER-TETRI B A, RINELLA M，et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med，2018,24(7):908-922. DOI：10.1038/s41591-018-0104-9.
[2]	ITO T, ISHIGAMI M, ISHIZU Y，et al. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients[J]. J Gastroenterol Hepatol，2019,34(1):207-214. DOI：10.1111/jgh.14448.
[3]	HUANG D Q, EL-SERAG H B, LOOMBA R. Global epidemiology of NAFLD-related HCC：trends，predictions，risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol，2021,18(4):223-238. DOI：10.1038/s41575-020-00381-6.
[4]	ORCI L A, SANDUZZI-ZAMPARELLI M, CABALLOL B，et al. Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease：a systematic review，meta-analysis，and meta-regression[J]. Clin Gastroenterol Hepatol，2022,20(2):283-292.e10. DOI：10.1016/j.cgh.2021.05.002.
[5]	KAYA E D, YILMAZ Y. Metabolic-associated fatty liver disease（MAFLD）：a multi-systemic disease beyond the liver[J]. J Clin Transl Hepatol，2022,10(2):329-338. DOI：10.14218/JCTH.2021.00178.
[6]	YE Q, ZOU B Y, YEO Y H，et al. Global prevalence，incidence，and outcomes of non-obese or lean non-alcoholic fatty liver disease：a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol，2020,5(8):739-752. DOI：10.1016/S2468-1253(20)30077-7.
[7]	RIAZI K, AZHARI H, CHARETTE J H，et al. The prevalence and incidence of NAFLD worldwide：a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol，2022,7(9):851-861. DOI：10.1016/S2468-1253(22)00165-0.
[8]	LONARDO A, NASCIMBENI F, BALLESTRI S，et al. Sex differences in nonalcoholic fatty liver disease：state of the art and identification of research gaps[J]. Hepatology，2019,70(4):1457-1469. DOI：10.1002/hep.30626.
[9]	ESTES C, ANSTEE Q M, ARIAS-LOSTE M T，et al. Modeling NAFLD disease burden in China，France，Germany，Italy，Japan，Spain，United Kingdom，and United States for the period 2016-2030[J]. J Hepatol，2018,69(4):896-904. DOI：10.1016/j.jhep.2018.05.036.
[10]	YOUNOSSI Z M, GOLABI P, PAIK J M，et al. The global epidemiology of nonalcoholic fatty liver disease（NAFLD）and nonalcoholic steatohepatitis（NASH）：a systematic review[J]. Hepatology，2023,77(4):1335-1347. DOI：10.1097/HEP.0000000000000004.
[11]	ZHOU J H, ZHOU F, WANG W X，et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology，2020,71(5):1851-1864. DOI：10.1002/hep.31150.
[12]	PARK J W, CHEN M S, COLOMBO M，et al. Global patterns of hepatocellular carcinoma management from diagnosis to death：the BRIDGE Study[J]. Liver Int，2015,35(9):2155-2166. DOI：10.1111/liv.12818.
[13]	TOKUSHIGE K, HASHIMOTO E, HORIE Y，et al. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease，alcoholic liver disease，and chronic liver disease of unknown etiology：report of the nationwide survey[J]. J Gastroenterol，2011,46(10):1230-1237. DOI：10.1007/s00535-011-0431-9.
[14]	GOH K L, RAZLAN H, HARTONO J L，et al. Liver cancer in Malaysia：epidemiology and clinical presentation in a multiracial Asian population[J]. J Dig Dis，2015,16(3):152-158. DOI：10.1111/1751-2980.12223.
[15]	LIEW Z H, GOH G B, HAO Y，et al. Comparison of hepatocellular carcinoma in patients with cryptogenic versus hepatitis B etiology：a study of 1079 cases over 3 decades[J]. Dig Dis Sci，2019,64(2):585-590. DOI：10.1007/s10620-018-5331-x.
[16]	ALJUMAH A A, KURIRY H, ALZUNAITAN M，et al. Clinical presentation，risk factors，and treatment modalities of hepatocellular carcinoma：a single tertiary care center experience[J]. Gastroenterol Res Pract，2016,2016:1989045. DOI：10.1155/2016/1989045.
[17]	SOMBOON K, SIRAMOLPIWAT S, VILAICHONE R K. Epidemiology and survival of hepatocellular carcinoma in the central region of Thailand[J]. Asian Pac J Cancer Prev，2014,15(8):3567-3570. DOI：10.7314/apjcp.2014.15.8.3567.
[18]	YUEN M F, HOU J L, CHUTAPUTTI A，et al. Hepatocellular carcinoma in the Asia Pacific region[J]. J Gastroenterol Hepatol，2009,24(3):346-353. DOI：10.1111/j.1440-1746.2009.05784.x.
[19]	PAUL S B, CHALAMALASETTY S B, VISHNUBHATLA S，et al. Clinical profile，etiology and therapeutic outcome in 324 hepatocellular carcinoma patients at a tertiary care center in India[J]. Oncology，2009,77(3/4):162-171. DOI：10.1159/000231886.
[20]	JASIRWAN C O M, HASAN I, SULAIMAN A S，et al. Risk factors of mortality in the patients with hepatocellular carcinoma：a multicenter study in Indonesia[J]. Curr Probl Cancer，2020,44(1):100480. DOI：10.1016/j.currproblcancer.2019.05.003.
[21]	DYSON J, JAQUES B, CHATTOPADYHAY D，et al. Hepatocellular cancer：the impact of obesity，type 2 diabetes and a multidisciplinary team[J]. J Hepatol，2014,60(1):110-117. DOI：10.1016/j.jhep.2013.08.011.
[22]	LOPES F D E L, COELHO F F, KRUGER J A，et al. Influence of hepatocellular carcinoma etiology in the survival after resection[J]. Braz Arch Dig Surg，2016,29(2):105-108. DOI：10.1590/0102-6720201600020010.
[23]	RAPTIS I, KOSKINAS J, EMMANOUIL T，et al. Changing relative roles of hepatitis B and C viruses in the aetiology of hepatocellular carcinoma in Greece. Epidemiological and clinical observations[J]. J Viral Hepat，2003,10(6):450-454. DOI：10.1046/j.1365-2893.2003.00442.x.
[24]	GANSLMAYER M, HAGEL A, DAUTH W，et al. A large cohort of patients with hepatocellular carcinoma in a single European centre：aetiology and prognosis now and in a historical cohort[J]. Swiss Med Wkly，2014,144:w13900. DOI：10.4414/smw.2014.13900.
[25]	PAIS R, FARTOUX L, GOUMARD C，et al. Temporal trends，clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period[J]. Aliment Pharmacol Ther，2017,46(9):856-863. DOI：10.1111/apt.14261.
[26]	WONG R J, CHEUNG R, AHMED A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.[J]. Hepatology，2014,59(6):2188-2195. DOI：10.1002/hep.26986.
[27]	HONG T P, GOW P, FINK M，et al. Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed[J]. Hepatology，2016,63(4):1205-1212. DOI：10.1002/hep.28267.
[28]	SEYDA SEYDEL G, KUCUKOGLU O, ALTINBASV A，et al. Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries[J]. Ann Hepatol，2016,15(5):662-672. DOI：10.5604/16652681.1212316.
[29]	ZHU J Z, ZHOU Q Y, WANG Y M，et al. Prevalence of fatty liver disease and the economy in China：a systematic review[J]. World J Gastroenterol，2015,21(18):5695-5706. DOI：10.3748/wjg.v21.i18.5695.
[30]	YANG J D, MOHAMED E A, AZIZ A O，et al. Characteristics，management，and outcomes of patients with hepatocellular carcinoma in Africa：a multicountry observational study from the Africa Liver Cancer Consortium[J]. Lancet Gastroenterol Hepatol，2017,2(2):103-111. DOI：10.1016/S2468-1253(16)30161-3.
[31]	FANZO J C, DOWNS S M. Climate change and nutrition-associated diseases[J]. Nat Rev Dis Primers，2021,7(1):90. DOI：10.1038/s41572-021-00329-3.
[32]	KOCH C A, SHARDA P, PATEL J，et al. Climate change and obesity[J]. Horm Metab Res，2021,53(9):575-587. DOI：10.1055/a-1533-2861.
[33]	BLÜHER M. Obesity：global epidemiology and pathogenesis[J]. Nat Rev Endocrinol，2019,15(5):288-298. DOI：10.1038/s41574-019-0176-8.
[34]	PAFILI K, RODEN M. Nonalcoholic fatty liver disease（NAFLD）from pathogenesis to treatment concepts in humans[J]. Mol Metab，2021,50:101122. DOI：10.1016/j.molmet.2020.101122.
[35]	SANTORO N, ZHANG C K, ZHAO H Y，et al. Variant in the glucokinase regulatory protein（GCKR）gene is associated with fatty liver in obese children and adolescents[J]. Hepatology，2012,55(3):781-789. DOI：10.1002/hep.24806.
[36]	STENDER S, KOZLITINA J, NORDESTGAARD B G，et al. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci[J]. Nat Genet，2017,49(6):842-847. DOI：10.1038/ng.3855.
[37]	KASPER P, MARTIN A, LANG S，et al. NAFLD and cardiovascular diseases：a clinical review[J]. Clin Res Cardiol，2021,110(7):921-937. DOI：10.1007/s00392-020-01709-7.
[38]	RADU F, POTCOVARU C G, SALMEN T，et al. The link between NAFLD and metabolic syndrome[J]. Diagnostics，2023,13(4):614. DOI：10.3390/diagnostics13040614.
[39]	KWAK J H, JUN D W, LEE S M，et al. Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease：a cross-sectional study[J]. Clin Nutr，2018,37(5):1550-1557. DOI：10.1016/j.clnu.2017.08.018.
[40]	KO E, YOON E L, JUN D W. Risk factors in nonalcoholic fatty liver disease[J]. Clin Mol Hepatol，2023,29(Suppl):S79-85. DOI：10.3350/cmh.2022.0398.
[41]	ENG J M, ESTALL J L. Diet-induced models of non-alcoholic fatty liver disease：food for thought on sugar，fat，and cholesterol[J]. Cells，2021,10(7):1805. DOI：10.3390/cells10071805.
[42]	YUAN S, CHEN J, LI X，et al. Lifestyle and metabolic factors for nonalcoholic fatty liver disease：mendelian randomization study[J]. Eur J Epidemiol，2022,37(7):723-733. DOI：10.1007/s10654-022-00868-3.
[43]	WU F T, PAHKALA K, JUONALA M，et al. Childhood and adulthood passive smoking and nonalcoholic fatty liver in midlife：a 31-year cohort study[J]. Am J Gastroenterol，2021,116(6):1256-1263. DOI：10.14309/ajg.0000000000001141.
[44]	MUMTAZ H, HAMEED M, SANGAH A B，et al. Association between smoking and non-alcoholic fatty liver disease in Southeast Asia[J]. Front Public Health，2022,10:1008878. DOI：10.3389/fpubh.2022.1008878.
[45]	JUNG H S, CHANG Y, KWON M J，et al. Smoking and the risk of non-alcoholic fatty liver disease：a cohort study[J]. Am J Gastroenterol，2019,114(3):453-463. DOI：10.1038/s41395-018-0283-5.
[46]	PREMKUMAR M, ANAND A C. Tobacco，cigarettes，and the liver：the smoking Gun[J]. J Clin Exp Hepatol，2021,11(6):700-712. DOI：10.1016/j.jceh.2021.07.016.
[47]	HAYAT U, SIDDIQUI A A, OKUT H，et al. The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis：a meta-analysis of 11 epidemiological studies[J]. Ann Hepatol，2021,20:100254. DOI：10.1016/j.aohep.2020.08.071.
[48]	ZHANG Y, LIU Z P, CHOUDHURY T，et al. Habitual coffee intake and risk for nonalcoholic fatty liver disease：a two-sample Mendelian randomization study[J]. Eur J Nutr，2021,60(4):1761-1767. DOI：10.1007/s00394-020-02369-z.
[49]	SANTOS R M M, LIMA D R A. Coffee consumption，obesity and type 2 diabetes：a mini-review[J]. Eur J Nutr，2016,55(4):1345-1358. DOI：10.1007/s00394-016-1206-0.
[50]	LOOPSTRA-MASTERS R C, LIESE A D, HAFFNER S M，et al. Associations between the intake of caffeinated and decaffeinated coffee and measures of insulin sensitivity and beta cell function[J]. Diabetologia，2011,54(2):320-328. DOI：10.1007/s00125-010-1957-8.
[51]	SIDORYK K, JAROMIN A, FILIPCZAK N，et al. Synthesis and antioxidant activity of caffeic acid derivatives[J]. Molecules，2018,23(9):2199. DOI：10.3390/molecules23092199.
[52]	SEO H Y, KIM M K, LEE S H，et al. Kahweol ameliorates the liver inflammation through the inhibition of NF-κB and STAT3 activation in primary kupffer cells and primary hepatocytes[J]. Nutrients，2018,10(7):863. DOI：10.3390/nu10070863.
[53]	BAJAJ J S, IDILMAN R, MABUDIAN L，et al. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort[J]. Hepatology，2018,68(1):234-247. DOI：10.1002/hep.29791.
[54]	KENNEDY O J, RODERICK P, BUCHANAN R，et al. Coffee，including caffeinated and decaffeinated coffee，and the risk of hepatocellular carcinoma：a systematic review and dose-response meta-analysis[J]. BMJ Open，2017,7(5):e013739. DOI：10.1136/bmjopen-2016-013739.
[55]	TAMURA T, HISHIDA A, WAKAI. Coffee consumption and liver cancer risk in Japan：a meta-analysis of six prospective cohort studies[J]. Nagoya J Med Sci，2019,81(1):143-150. DOI：10.18999/nagjms.81.1.143.
[56]	TAMURA T, WADA K, KONISHI K，et al. Coffee，green tea，and caffeine intake and liver cancer risk：a prospective cohort study[J]. Nutr Cancer，2018,70(8):1210-1216. DOI：10.1080/01635581.2018.1512638.
[57]	VAN DAM R M, HU F B, WILLETT W C. Coffee，caffeine，and health[J]. N Engl J Med，2020,383(4):369-378. DOI：10.1056/NEJMra1816604.
[58]	WONGTRAKUL W, NILTWAT S, CHARATCHAROENWITTHAYA P. The effects of modest alcohol consumption on non-alcoholic fatty liver disease：a systematic review and meta-analysis[J]. Front Med，2021,8:744713. DOI：10.3389/fmed.2021.744713.
[59]	AJMERA V, BELT P, WILSON L A，et al. Among patients with nonalcoholic fatty liver disease，modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis[J]. Clin Gastroenterol Hepatol，2018,16(9):1511-1520.e5. DOI：10.1016/j.cgh.2018.01.026.
[60]	ROERECKE M, VAFAEI A, HASAN O S M，et al. Alcohol consumption and risk of liver cirrhosis：a systematic review and meta-analysis[J]. Am J Gastroenterol，2019,114(10):1574-1586. DOI：10.14309/ajg.0000000000000340.
[61]	ÅBERG F, BYRNE C D, PIROLA C J，et al. Alcohol consumption and metabolic syndrome：clinical and epidemiological impact on liver disease[J]. J Hepatol，2023,78(1):191-206. DOI：10.1016/j.jhep.2022.08.030.
[62]	ALBILLOS A, GOTTARDI A D, RESCIGNO M. The gut-liver axis in liver disease：Pathophysiological basis for therapy[J]. J Hepatol，2020,72(3):558-577. DOI：10.1016/j.jhep.2019.10.003.
[63]	ZHANG D, HAO X X, XU L L，et al. Intestinal flora imbalance promotes alcohol-induced liver fibrosis by the TGFβ/smad signaling pathway in mice[J]. Oncol Lett，2017,14(4):4511-4516. DOI：10.3892/ol.2017.6762.
[64]	CHEN Y W, ZHOU J H, WANG L. Role and mechanism of gut microbiota in human disease[J]. Front Cell Infect Microbiol，2021,11:625913. DOI：10.3389/fcimb.2021.625913.
[65]	WANG D Z, YAN S, YAN J，et al. Effects of triphenyl phosphate exposure during fetal development on obesity and metabolic dysfunctions in adult mice：impaired lipid metabolism and intestinal dysbiosis[J]. Environ Pollut，2019,246:630-638. DOI：10.1016/j.envpol.2018.12.053.
[66]	ZHU L X, BAKER R D, ZHU R X，et al. Gut microbiota produce alcohol and contribute to NAFLD[J]. Gut，2016,65(7):1232. DOI：10.1136/gutjnl-2016-311571.
[67]	DE FARIA GHETTI F, OLIVEIRA D G, DE OLIVEIRA J M，et al. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis[J]. Eur J Nutr，2018,57(3):861-876. DOI：10.1007/s00394-017-1524-x.
[68]	FEDERICO A, DALLIO M, GODOS J，et al. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis：translational and clinical evidence[J]. Transl Res，2016,167(1):116-124. DOI：10.1016/j.trsl.2015.08.002.
[69]	LI F X, YE J Z, SHAO C X，et al. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients：a systematic review and meta-analysis[J]. Lipids Health Dis，2021,20(1):22. DOI：10.1186/s12944-021-01440-w.
[70]	OH T G, KIM S M, CAUSSY C，et al. A universal gut-microbiome-derived signature predicts cirrhosis[J]. Cell Metab，2020,32(5):901. DOI：10.1016/j.cmet.2020.10.015.
[71]	YUAN J, CHEN C, CUI J H，et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae[J]. Cell Metab，2019,30(6):1172. DOI：10.1016/j.cmet.2019.11.006.
[72]	HU H M, LIN A Z, KONG M W，et al. Intestinal microbiome and NAFLD：molecular insights and therapeutic perspectives[J]. J Gastroenterol，2020,55(2):142-158. DOI：10.1007/s00535-019-01649-8.
[73]	BOURSIER J, MUELLER O, BARRET M，et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J]. Hepatology，2016,63(3):764-775. DOI：10.1002/hep.28356.
[74]	NEWSOME P N, SASSO M, DEEKS J J，et al. FibroScan-AST（FAST）score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis：a prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol，2020,5(4):362-373. DOI：10.1016/S2468-1253(19)30383-8.
[75]	FANG J, YU C H, LI X J，et al. Gut dysbiosis in nonalcoholic fatty liver disease：pathogenesis，diagnosis，and therapeutic implications[J]. Front Cell Infect Microbiol，2022,12:997018. DOI：10.3389/fcimb.2022.997018.
[76]	REN R R, ZHENG Y. Sex differences in cardiovascular and all-cause mortality in nonalcoholic fatty liver disease in the US population[J]. Nutr Metab Cardiovasc Dis，2023,33(7):1349-1357. DOI：10.1016/j.numecd.2023.03.003.
[77]	DISTEFANO J K. NAFLD and NASH in postmenopausal women：implications for diagnosis and treatment[J]. Endocrinology，2020,161(10):bqaa134. DOI：10.1210/endocr/bqaa134.
[78]	PALMISANO B T, ZHU L, STAFFORD J M. Role of estrogens in the regulation of liver lipid metabolism[J]. Adv Exp Med Biol，2017,1043:227-256. DOI：10.1007/978-3-319-70178-3_12.
[79]	JARUVONGVANICH V, SANGUANKEO A, RIANGWIWAT T，et al. Testosterone，sex hormone-binding globulin and nonalcoholic fatty liver disease：a systematic review and meta-analysis[J]. Ann Hepatol，2017,16(3):382-394. DOI：10.5604/16652681.1235481.
[80]	DONNELLY M C, STABLEFORTH W, KRAG A，et al. The negative bidirectional interaction between climate change and the prevalence and care of liver disease：a joint BSG，BASL，EASL，and AASLD commentary[J]. J Hepatol，2022,76(5):995-1000. DOI：10.1016/j.jhep.2022.02.012.
[81]	LI W, XIAO H T, WU H，et al. Analysis of environmental chemical mixtures and nonalcoholic fatty liver disease：NHANES 1999-2014[J]. Environ Pollut，2022,311:119915. DOI：10.1016/j.envpol.2022.119915.
[82]	KANAZAWA S. Does global warming contribute to the obesity epidemic?[J]. Environ Res，2020,182:108962. DOI：10.1016/j.envres.2019.108962.
[83]	HADLEY K, WHEAT S, ROGERS H H，et al. Mechanisms underlying food insecurity in the aftermath of climate-related shocks：a systematic review[J]. Lancet Planet Health，2023,7(3):e242-250. DOI：10.1016/S2542-5196(23)00003-7.
[84]	CANO R, PÉREZ J L, DÁVILA L A，et al. Role of endocrine-disrupting chemicals in the pathogenesis of non-alcoholic fatty liver disease：a comprehensive review[J]. Int J Mol Sci，2021,22(9):4807. DOI：10.3390/ijms22094807.
[85]	ZHANG X Y, ZHAO L G, DUCATMAN A，et al. Association of per- and polyfluoroalkyl substance exposure with fatty liver disease risk in US adults[J]. JHEP Rep，2023,5(5):100694. DOI：10.1016/j.jhepr.2023.100694.
[86]	AN S J, YANG E J, OH S，et al. The association between urinary bisphenol A levels and nonalcoholic fatty liver disease in Korean adults：Korean National Environmental Health Survey（KoNEHS）2015-2017[J]. Environ Health Prev Med，2021,26(1):91. DOI：10.1186/s12199-021-01010-7.
[87]	FLING R R, ZACHAREWSKI T R. Aryl hydrocarbon receptor（AhR）activation by 2，3，7，8-tetrachlorodibenzo- p-dioxin（TCDD）dose-dependently shifts the gut microbiome consistent with the progression of non-alcoholic fatty liver disease[J]. Int J Mol Sci，2021,22(22):12431. DOI：10.3390/ijms222212431.
[88]	ZHU X Y, XIA H G, WANG Z H，et al. In vitro and in vivo approaches for identifying the role of aryl hydrocarbon receptor in the development of nonalcoholic fatty liver disease[J]. Toxicol Lett，2020,319:85-94. DOI：10.1016/j.toxlet.2019.10.010.
[89]	KIM K, MELOUGH M M, VANCE T M，et al. Dietary cadmium intake and sources in the US[J]. Nutrients，2018,11(1):2. DOI：10.3390/nu11010002.
[90]	LI Y X, CHEN C, LU L P，et al. Cadmium exposure in young adulthood is associated with risk of nonalcoholic fatty liver disease in midlife[J]. Dig Dis Sci，2022,67(2):689-696. DOI：10.1007/s10620-021-06869-8.
[91]	PARK E, KIM J, KIM B，et al. Association between environmental exposure to cadmium and risk of suspected non-alcoholic fatty liver disease[J]. Chemosphere，2021,266:128947. DOI：10.1016/j.chemosphere.2020.128947.
[92]	CAVE M, APPANA S, PATEL M，et al. Polychlorinated biphenyls，lead，and mercury are associated with liver disease in American adults：NHANES 2003-2004[J]. Environ Health Perspect，2010,118(12):1735-1742. DOI：10.1289/ehp.1002720.
[93]	FREDIANI J K, NAIOTI E A, VOS M B，et al. Arsenic exposure and risk of nonalcoholic fatty liver disease（NAFLD）among U.S. adolescents and adults：an association modified by race/ethnicity，NHANES 2005-2014[J]. Environ Health，2018,17(1):6. DOI：10.1186/s12940-017-0350-1.
[94]	YANG C Y, LI Y Y, DING R，et al. Lead exposure as a causative factor for metabolic associated fatty liver disease（MAFLD）and a lead exposure related nomogram for MAFLD prevalence[J]. Front Public Health，2022,10:1000403. DOI：10.3389/fpubh.2022.1000403.
[95]	YOUNG J L, CAVE M C, XU Q，et al. Whole life exposure to low dose cadmium alters diet-induced NAFLD[J]. Toxicol Appl Pharmacol，2022,436:115855. DOI：10.1016/j.taap.2021.115855.
[96]	GU J, KONG A Q, GUO C Z，et al. Cadmium perturbed lipid profile and induced liver dysfunction in mice through phosphatidylcholine remodeling and promoting arachidonic acid synthesis and metabolism[J]. Ecotoxicol Environ Saf，2022,247:114254. DOI：10.1016/j.ecoenv.2022.114254.
[97]	QIU T M, PEI P, YAO X F，et al. Taurine attenuates arsenic-induced pyroptosis and nonalcoholic steatohepatitis by inhibiting the autophagic-inflammasomal pathway[J]. Cell Death Dis，2018,9(10):946. DOI：10.1038/s41419-018-1004-0.
[98]	CHEN H G, ZHU C X, ZHOU X. Effects of lead and cadmium combined heavy metals on liver function and lipid metabolism in mice[J]. Biol Trace Elem Res，2023,201(6):2864-2876. DOI：10.1007/s12011-022-03390-5.
[99]	AUGUET T, BERTRAN L, BARRIENTOS-RIOSALIDO A，et al. Are ingested or inhaled microplastics involved in nonalcoholic fatty liver disease?[J]. Int J Environ Res Public Health，2022,19(20):13495. DOI：10.3390/ijerph192013495.
[100]	LI L, XU M J, HE C，et al. Polystyrene nanoplastics potentiate the development of hepatic fibrosis in high fat diet fed mice[J]. Environ Toxicol，2022,37(2):362-372. DOI：10.1002/tox.23404.
[101]	YIN J L, JU Y, QIAN H H，et al. Nanoplastics and microplastics may be damaging our livers[J]. Toxics，2022,10(10):586. DOI：10.3390/toxics10100586.
[102]	YEE M S, HII L W, LOOI C K，et al. Impact of microplastics and nanoplastics on human health[J]. Nanomaterials，2021,11(2):496. DOI：10.3390/nano11020496.
[103]	CHENG W, LI X L, ZHOU Y，et al. Polystyrene microplastics induce hepatotoxicity and disrupt lipid metabolism in the liver organoids[J]. Sci Total Environ，2022,806(Pt 1):150328. DOI：10.1016/j.scitotenv.2021.150328.
[104]	LAI W C, XU D, LI J M，et al. Dietary polystyrene nanoplastics exposure alters liver lipid metabolism and muscle nutritional quality in carnivorous marine fish large yellow croaker（Larimichthys crocea）[J]. J Hazard Mater，2021,419:126454. DOI：10.1016/j.jhazmat.2021.126454.
[105]	THANGAVEL P, PARK D, LEE Y C. Recent insights into particulate matter（PM2.5）-mediated toxicity in humans：an overview[J]. Int J Environ Res Public Health，2022,19(12):7511. DOI：10.3390/ijerph19127511.
[106]	SUN S Z, YANG Q Q, ZHOU Q X，et al. Long-term exposure to fine particulate matter and non-alcoholic fatty liver disease：a prospective cohort study[J]. Gut，2022,71(2):443-445. DOI：10.1136/gutjnl-2021-324364.
[107]	XU J X, ZHANG W, LU Z B，et al. Airborne PM2.5-induced hepatic insulin resistance by Nrf2/JNK-mediated signaling pathway[J]. Int J Environ Res Public Health，2017,14(7):787. DOI：10.3390/ijerph14070787.
[108]	XU Z J, SHI L M, LI D C，et al. Real ambient particulate matter-induced lipid metabolism disorder：roles of peroxisome proliferators-activated receptor alpha[J]. Ecotoxicol Environ Saf，2022,231:113173. DOI：10.1016/j.ecoenv.2022.113173.
[109]	XU X H, LIU C Q, XU Z B，et al. Long-term exposure to ambient fine particulate pollution induces insulin resistance and mitochondrial alteration in adipose tissue[J]. Toxicol Sci，2011,124(1):88-98. DOI：10.1093/toxsci/kfr211.
[110]	FERRO D, BARATTA F, PASTORI D，et al. New insights into the pathogenesis of non-alcoholic fatty liver disease：gut-derived lipopolysaccharides and oxidative stress[J]. Nutrients，2020,12(9):2762. DOI：10.3390/nu12092762.
[111]	LONG M H, ZHANG C, XU D Q，et al. PM2.5 aggravates diabetes via the systemically activated IL-6-mediated STAT3/SOCS3 pathway in rats' liver[J]. Environ Pollut，2020,256:113342. DOI：10.1016/j.envpol.2019.113342.
[112]	LI R, SUN Q, LAM S M，et al. Sex-dependent effects of ambient PM2.5 pollution on insulin sensitivity and hepatic lipid metabolism in mice[J]. Part Fibre Toxicol，2020,17(1):14. DOI：10.1186/s12989-020-00343-5.

国家	归因于NAFLD发展的HCC比例	统计时间人均GDP（美元）	参考文献	统计时间（中期时间）
中国	1.0	3 468.33	PARK等^[12]	2005—2011（2008）
日本	2.0	39 876.31	TOKUSHIGE等^[13]	2006—2009（2008）
韩国	6.0	21 350.43	PARK等^[12]	2005—2011（2008）
马来西亚	16.4	8 343.30	GOH等^[14]	2006—2009（2008）
新加坡	20.4	53 891.46	LIEW等^[15]	1980—2015（2011）
沙特阿拉伯	21.7	17 958.95	ALJUMAH等^[16]	2009—2011（2010）
泰国	16.0	4 996.37	SOMBOON等^[17]	2007—2012（2010）
菲律宾	24.9	1 990.36	YUEN等^[18]	2008—2008（2008）
印度	21.6	412.51	PAUL等^[19]	1990—2005（1998）
印度尼西亚	16.3	3 558.82	JASIRWAN等^[20]	2015—2017（2016）
英国	34.8	39 693.19	DYSON等^[21]	2000—2010（2010）
巴西	7.9	7 323.19	LOPES等^[22]	2000—2014（2007）
希腊	9.0	13 472.14	RAPTIS等^[23]	1996—2000（1998）
德国	20.0	36 353.88	GANSLMAYER等^[24]	1999—2013（2006）
法国	12.0	34 768.18	PAIS等^[25]	1995—2014（2005）
美国	13.5	51 784.42	WONG等^[26]	2002—2012（2012）
澳大利亚	14.0	68 047.38	HONG等^[27]	2012—2013（2012）
埃及	12.0	2 645.62	YANG等^[30]	2006—2016（2011）
非洲其他国家	22.0	1 501.06	YANG等^[30]	2006—2016（2011）

国家	归因于NAFLD发展的HCC比例	统计时间人均GDP（美元）	参考文献	统计时间（中期时间）
中国	1.0	3 468.33	PARK等^[12]	2005—2011（2008）
日本	2.0	39 876.31	TOKUSHIGE等^[13]	2006—2009（2008）
韩国	6.0	21 350.43	PARK等^[12]	2005—2011（2008）
马来西亚	16.4	8 343.30	GOH等^[14]	2006—2009（2008）
新加坡	20.4	53 891.46	LIEW等^[15]	1980—2015（2011）
沙特阿拉伯	21.7	17 958.95	ALJUMAH等^[16]	2009—2011（2010）
泰国	16.0	4 996.37	SOMBOON等^[17]	2007—2012（2010）
菲律宾	24.9	1 990.36	YUEN等^[18]	2008—2008（2008）
印度	21.6	412.51	PAUL等^[19]	1990—2005（1998）
印度尼西亚	16.3	3 558.82	JASIRWAN等^[20]	2015—2017（2016）
英国	34.8	39 693.19	DYSON等^[21]	2000—2010（2010）
巴西	7.9	7 323.19	LOPES等^[22]	2000—2014（2007）
希腊	9.0	13 472.14	RAPTIS等^[23]	1996—2000（1998）
德国	20.0	36 353.88	GANSLMAYER等^[24]	1999—2013（2006）
法国	12.0	34 768.18	PAIS等^[25]	1995—2014（2005）
美国	13.5	51 784.42	WONG等^[26]	2002—2012（2012）
澳大利亚	14.0	68 047.38	HONG等^[27]	2012—2013（2012）
埃及	12.0	2 645.62	YANG等^[30]	2006—2016（2011）
非洲其他国家	22.0	1 501.06	YANG等^[30]	2006—2016（2011）